急性心肌梗死患者血清可溶性CD40配体和纤维蛋白原的改变及其临床意义被引量：3

Soluble CD40 Ligand and fibrinogen in acute myocardial infarction

导出

摘要目的观察急性心肌梗死患者血清可溶性CIM0配体（sCD40L）水平和血浆纤维蛋白原（Fg）的变化以及与临床预后的关系。方法采用酶联免疫吸附法测定60例急性心肌梗死患者血清sCIMOL水平，用全自动血凝分析仪测定血浆吒，患者出院后随访2年，观察心血管事件。结果急性心肌梗死患者sCD40L水平（15．36±7．32）μg/L显著高于正常对照组（5．79±2．78）μg／L（P〈0．001）。急性心肌梗死患者中Fg水平（4．60±1．37）g/L显著高于正常对照组（3．03±0．82）g/L（P〈0．001）。发生心血管事件患者的sCD40L（18．144±6．34）μg/L和Fg（4．974±1．33）g/L显著高于无心血管临床事件患者的sCD40L（14.38±6．67）μg/L和Fg（4．20±1．24）g／L（P〈0．05）。sCD40L水平≥14．5μg/L或Fg≥4．4g／L的患者的心血管事件发生增多（P〈0．05）。合并糖尿病的急性心肌梗死患者sCD40L水平（18．38±6．71）μg/L显著高于不合并糖尿病的急性心肌梗死患者（14．464±6．48）μg/L（P〈0．05）。相关性分析显示在AMI患者中sCD40L与Fg正相关（r=0．27，P〈0．05），瞻与左室射血分数负相关（r=-0．319，P〈0．05）。结论急性心肌梗死患者血清sCIMOL水平和Fg升高，sCD40L和Fg明显升高的患者发生心血管事件的风险明显升高，糖尿病是sCD40L升高的临床危险因素，sCD40L和Fg是急性心肌梗死患者的预后指标，在急性心肌梗死的病理生理过程中起重要作用。 Objective To observe the changes of serum soluble CD40 ligand （sCIMOL） and fibrinogen in acute myocardial infarction （AMI） patients and to investigate the clinical predictive value of increased serum sCD40L and fibrinogen. Methods Serum sCD40L level of 60 AMI patients was determined by enzyme-linked immunosorhent assay （ ELISA ）. Plasma level of fibrinogen was measured. The patients were followed up for 2 years after discharge from the hospital and were observed for cardiovascular event. Results AMI patients had higher sCD40L and fibrinogen levels than those of controls [ （ 15.36 ± 7.32 ） μg/L vs. （ 5.79 ± 2.78 ） μg,/L, （ 4.60 ±1. 37 ） g/L vs. （ 3.03 ± 0. 82） g/L, P 〈 0.001 ], which were significantly higher in the patients experiencing cardiovascular event than those without cardiovascular event [ （ 18. 14 ± 6.34 ） μg/L vs. （ 14.38 ± 6.67 ） μg/L and （4.97 ± 1.33 ） μg/L vs. （4.20 ± 1.24 ） g/L ] （ P 〈 0.05 ）. The patients with sCD40L ≥ 14.5 μg/L or fibrinogen≥ 4.4 g/L experienced increased risk of adverse cardiovascular events （ P 〈 0.05 ）. In AMI patients, sCD40L level was significantly higher in patients with diabetes than in nondiabetics [ （ 18.38 ± 6.71 ） μg/L vs. （ 14.46 ±6.48 ） μg/L, P 〈 0.05 ） ]. Fibrinogen level was related to sCD40L （ r = 0.27, P 〈 0.05 ） and LVEF （ r = - 0.319, P 〈 0.05 ）. Conclusion Increased sCD40L and fibrinogen levels, which maybe related to the pathogenesis of AMI, can be found in AMI patients and can indicate an independent increased risk of major adverse cardiovascular events. Diabetes is independently associated with elevated sCD40L level in AMI patients.

作者王华杨杰孚张传宝刘芳包承鑫张闻多褚德发范海荣

机构地区北京医院心内科北京医院神经内科北京医院统计室北京医院卫生部临检中心中国医学科学院血液学研究所

出处《中国综合临床》北大核心 2008年第12期1244-1246,共3页 Clinical Medicine of China

关键词急性心肌梗死纤维蛋白原 SCD40L Acute myocardial infarction Fibrinogen sCD40L

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Tousoulis D, Antoniades C, Nikolopoulou A, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes [ J ]. Eur J Clin Invest,2007,37 ( 8 ) :623-628.
2Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease [ J ]. Circulation, 2002,106 ( 8 ) : 896-899.
3Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes [ J ]. Circulation, 2003, 108 ( 9 ) : 1049-1052.
4Yan JC,Zhu J,Gao L,et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes [ J ]. Clin Chim Acta,2004,343 (1-2) : 155-159.
5Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand : a novel target in the fight against cardiovascular disease[ J]. Ann Pharmacother,2004,38(9) :1500-1508.
6Heesehen C, Dimmeler S, Hamm CW, et al. CAPTURE Study Investigators Soluble CIM0 ligand in acute coronary syndromes [ J ]. N Engl J Med,2003,348(12) :1104-1111.
7Morange PE, Bickel C, Nicaud V, et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease the atherogene study [ J ]. Arterioscler Thromb Vasc Biol, 2006,26 (12) :2793-2799.
8Lira HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin,interleukin-6, and tissue factor in diabetes mellitus : relationships to cardiovascular disease and risk factor intervention [ J ]. Circulation,2004,109 (21) :2524-2528.
9Grant PJ. Diabetes mellitus as a prothrombotic condition [ J ]. J Intern Med, 2007, 262(2) :157-172.
10Gibbs CR,Blann AD,Watson RD,et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm : effects of angintensin-converting enzyme inhibitor and beta-blocker therapy[ J]. Circulation,2001,103 (13) : 1746-1751.